Observers Expect Fewer Large Acquisitions By Indian Drug Makers This Year
This article was originally published in PharmAsia News
Executive Summary
Few large acquisitions by Indian drug makers are expected this year as those who took part in expanding the past two years sit back and take stock of their investments, experts say. The new caution is attributed to the failure of recent acquisitions to bring about anticipated results, according to industry observers. In 2006, Indian firms invested $1.2 billion in overseas acquisitions. In 2007, the amount dropped to $500 million. The observers cite pricing pressures in the United States and Europe for the fallback, along with longer waits for the acquisitions to pay off. (Click here for more
|
Few large acquisitions by Indian drug makers are expected this year as those who took part in expanding the past two years sit back and take stock of their investments, experts say. The new caution is attributed to the failure of recent acquisitions to bring about anticipated results, according to industry observers. In 2006, Indian firms invested $1.2 billion in overseas acquisitions. In 2007, the amount dropped to $500 million. The observers cite pricing pressures in the United States and Europe for the fallback, along with longer waits for the acquisitions to pay off. (Click here for more) "Pharma Companies Wary Of Overseas Deals On Pricing Pressure" - Economic Times (India) (2/11/08) |